Patient Group Direction for the Administration of Hepatitis A vaccine

Similar documents
PGD for Td/IPV. Version number: 1.1

Patient Group Direction for the Administration of Human Papilloma Virus (HPV) Vaccine (Gardasil and Cervarix )

Patient Group Direction for the Administration of Haemophilus Influenzae Type b and Meningococcal C conjugated vaccine (Hib/MenC - Menitorex )

Patient Group Direction (PGD) for the Administration of BCG Vaccine

Patient Group Direction (PGD) for the Administration of Fluenz Nasal Spray Suspension (Influenza Vaccine, Live)

Patient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start Date: 1 st July 2015 Expiry Date:30 th June 2018

GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

Clinical Condition Indication:

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the

Patient Group Direction for Combined Hepatitis A & B vaccine Version: Hep A + B Start Date: 1 st January 2014 Expiry Date: 31 st December 2015

Patient Group Direction For the supply and administration of

Administration of Hepatitis A and B Vaccine

Direction Number: - NECSAT 2015/001

Document Details. Patient Group Direction

Community Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services

Patient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine

Clinical Condition Indication:

GG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

GG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

This document expires on Patient Group Direction No. VI 11

Patient Group Direction For the supply and administration of

This document expires on Patient Group Direction No. VI 7

Patient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st May 2014 Expiry Date: 30 th April 2017

NATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION

Patient Group Direction For the supply and administration of

Patient Group Direction

patient group direction

Document Details. Patient Group Direction

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml

Patient Group Direction For the supply and administration of

Patient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st April 2016 Expiry Date: 31 st March 2019

CLINICAL CONTENT OF PATIENT GROUP DIRECTION FOR PNEUMOCOCCAL CONJUGATE VACCINE (Prevenar 13 )

This document expires on Patient Group Direction No. VI 5

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group

Patient Group Directions (PGDs)

HEPATITIS A + TYPHOID VACCINE

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017

THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:

Prescription only medicines (POMs)

Change history Version number Change details Date Updated for National ACWY programme to be implemented August June 2015.

PATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )

Guideline on the use of Hepatitis A&B Immunisations for Immunocompromised and Immunocompetent Hepatology Patients

GG&C PGD ref no: 2018/1589 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

CALDERDALE PRIMARY CARE TRUST

Patient Group Direction for Rotavirus vaccine Version: ROTAVIRUS (Rotarix ) Start Date: 1 st July 2013 Expiry Date:30 th June 2015

GG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

HAVRIX 1440 and HAVRIX Junior

Staff Immunisation Policy

Patient Group Direction For the supply and administration of

Patient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019

PATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine

Expiry Date: September 2009 Template Version: Page 1 of 7

What s the latest on the staff vaccination programme for swine flu?

This Patient Group Direction has been developed/reviewed in accordance with NICE guidance by:- Position of Signatory Name Signed Date

Patient Group Direction for the Supply of Orlistat (Xenical) from Designated Community Pharmacies

Hepatitis B in Travellers

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OR ADMINISTRATION OF LEVONORGESTREL 1500 MICROGRAM TABLET (e.g LEVONELLE 1500 ) PGD

Some general information on hepatitis A infection is given at the end of this leaflet.

patient group direction

CONJUGATE MENINGOCOCCAL (ACWY) VACCINE

Direction Number: - NECSAT 2014/017

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

PATIENT GROUP DIRECTION PROCEDURE

Clinical Condition Indication:

Case scenarios: Patient Group Directions

SAMPLE. PGD Reviewed by: Chris Faldon, John Maloney, Tim Patterson, Adrian MacKenzie, Claire Stein

SAMPLE. PGD reviewed by: Dr Tim Patterson, Chris Faldon, John Maloney, Adrian Mackenzie

Patient Group Direction

patient group direction

INFECTION PREVENTION AND CONTROL POLICY AND PROCEDURES Sussex Partnership NHS Foundation Trust (The Trust)

HEPATYRIX (Combined inactivated hepatitis A and Vi polysaccharide typhoid vaccine) CONSUMER MEDICINE INFORMATION LEAFLET

Hepatitis A is a small, unenveloped, symmetrical RNA virus within the genus Hepatovirus, a member of the Picornavirus family.

Havrix 1440 Adult / 720 Junior Inactivated hepatitis A vaccine

Havrix 1440 Adult / 720 Junior Inactivated hepatitis A vaccine

Patient Group Directions Policy

PATIENT GROUP DIRECTION

Template Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices

EAST LONDON INTEGRATED CARE

Consultation Group: See relevant page in the PGD. Review Date: October 2017

PATIENT GROUP DIRECTION FOR THE SUPPLY OF ORLISTAT BY COMMUNITY PHARMACISTS

Version Number: 02. Patient Group Direction drawn up by: Jayne Bruce - Deputy Director of Nursing Standards and Safety Sussex

NHS Lothian Patient Group Direction Version: 006

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019

PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY

Patient Group Direction for LIDOCAINE INJECTION (Version 02) Valid From 1 October September 2019

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE

Patient Group Direction for LEVONELLE (Version 02) Valid From 1 October September 2019

Seventh-day Adventist Schools (South Queensland) Limited

PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms)

standards for vaccinators and guidelines for organisations offering immunisation services

Direction Number: - NECSAT 2017/004

PATIENT GROUP DIRECTION (PGD)

Patient Group Direction (PGD)

Direction Number: - NECSAT 2014/007

patient group direction

This document expires on Patient Group Direction Number VI 19

Havrix TM 1440 Adult / 720 Junior

Consultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off

Transcription:

Patient Group Direction for the Administration of Hepatitis A vaccine This PGD must be read in conjunction with the core PGD (Reference: NHSE(LR)/PGD/Core PGD for Immunisations), which details information that is common to all of the immunisation PGDs. This PGD must only be used by registered healthcare professionals, working within, who have been named and authorised to practice under it. Version number: 1.1 The master copy for this PGD is held N:\2.0 Medical\Clinical Adviser Medicines\Patient Group Directions\Final Signed PGDs\Immunisation PGDs 2014 Change history Version Change details Date number 1.0 First version December 2013 1.1 Revision of content March 2014 Reference Number: NHSE(LR)/PGD/Hep A v1.1 Page 1 of 6

PGD Development and Clinical Approval PGD Working Group This PGD was developed by a working group involving pharmacists from a number of Clinical Commissioning Groups across London, plus nurse representatives. Name and role Jonathan Mason Pharmacist and Lead Author Henrietta Hughes Doctor Eileen Bryant Nurse reviewer Nicola Pratelli Nurse Reviewer Thara Raj Public Health Specialist Nick Beavon Raana Ali Pauline Taylor Helen Tsang Dee Vadukul Seema Buckley Job title and organisation Clinical Adviser (Medicines) Medical Director North Central and East London Area Team Primary Care Nurse Adviser Population Health Practitioner Manager Immunisation South London Public Health Specialist (Immunisation) and Acting Public Health Consultant (Health in the Justice System) Chief Pharmacist Wandsworth Clinical Commissioning Group Senior Prescribing Adviser (Tower Hamlets) North and East London Commissioning Support Unit Head of Medicines Management Haringey Clinical Commissioning Group Practice Link Pharmacist North West London Commissioning Support Unit Senior Practice Pharmacist Richmond Clinical Commissioning Group Chief Pharmacist NHS Kingston Clinical Commissioning Group References: SmPC References for Avaxim, Epaxal, Havrix (Monodose and Junior Monodose) and Vaqta. (Adult and Paediatric) Latest versions on emc (accessed March 2014): http://www.medicines.org.uk/emcmobile/medicine/6206/spc http://www.medicines.org.uk/emcmobile/medicine/26275/spc http://www.medicines.org.uk/emcmobile/medicine/2040/spc http://www.medicines.org.uk/emcmobile/medicine/2041/spc http://www.medicines.org.uk/emcmobile/medicine/6210/spc http://www.medicines.org.uk/emcmobile/medicine/6211/spc Green Book chapter on Hepatitis A vaccine (accessed March 2014): https://www.gov.uk/government/publications/hepatitis-a-the-green-book-chapter- 17 Reference Number: NHSE(LR)/PGD/Hep A v1.1 Page 2 of 6

PGD for Hep A Reference Number: NHSE(LR)/PGD/Hep A v1.1 st Valid from: 1 April 2014 st Review date: 1 January 2016 st Expiry date: 31 March 2016 Page 3 of 6

Patient Group Direction for the Administration of Hepatitis A vaccine Clinical condition or situation to which this PGD applies Inclusion criteria Active immunisation against Hepatitis A Adults and children over 1 year old, in the following groups: Patients travelling to areas of moderate or high endemicity for prolonged periods. Includes those posted to or going to reside in virus endemic countries; Patients with chronic liver disease, including those with hepatitis B, or hepatitis C; Occupational exposure, including laboratory workers working directly with the virus, those in contact with raw sewage, staff and residents of large institutions for those with learning disabilities, individuals who work with primates; Injecting drug users; Those at risk due to sexual behaviour, e.g. men who have sex with men; Haemophiliacs treated with plasma-derived clotting factors; Previously unvaccinated contacts of cases of hepatitis A with onset of jaundice within the last week; Previously unvaccinated contacts of a food handler who develops acute jaundice or is diagnosed clinically or serologically with hepatitis A infection, following guidance from the local Health Protection Team. Other groups such as food packagers/handlers, staff in day-care facilities, healthcare workers should not routinely be offered hepatitis A vaccination, however this PGD enables vaccination of other groups, following guidance from the local Health Protection Team, in response to local outbreaks. Exclusion criteria As per the general exclusion criteria stated in the Core PGD, plus: Child under 12 months of age; Previous hypersensitivity reaction to any constituent of the vaccine, in particular: o Confirmed anaphylactic reaction to egg/chick protein: Epaxal o Formaldehyde: Avaxim, Epaxal, Vaqta o Neomycin: Avaxim, Havrix, Vaqta ; In latex-sensitive individuals Vaqta may cause allergic reactions, use a different vaccine for these patients; Reference Number: NHSE(LR)/PGD/Hep A v1.1 Page 4 of 6

Confirmed history of Hepatitis A infection; Patients on haemodialysis (refer to specialist). Special considerations/ additional information Hepatitis A containing vaccines may be given to pregnant women who are at risk of contracting the disease; There is no evidence of risk from vaccinating pregnant women, or those who are breast-feeding with inactivated viral or bacterial vaccines or toxoids. Hepatitis A is an inactivated vaccine. Details of the medicine Name, form and strength of medicine Dose Hepatitis A vaccine (inactivated, adsorbed). Avaxim, Epaxal, Havrix, or Vaqta 1 year and over Epaxal : 0.5ml 1 15 years Havrix Monodose Junior : 0.5ml 1 17 years Vaqta Paediatric : 0.5ml 16 years and over Avaxim : 0.5ml Havrix Monodose : 1.0ml 18 years and over Vaqta : 1.0ml Frequency Quantity Adverse effects Initial dose, followed by booster dose as follows: Avaxim, Havrix Monodose, or Havrix Monodose Junior : 6 12 months (can be given up to 3 years after initial dose); Epaxal : 6-12 months (can be given up to 4 years after initial dose); Vaqta, or Vaqta Paediatric : 6 18 months; a booster can be given 6-12 months after the initial dose if a different brand was used for the initial dose. 2 doses As detailed in the core PGD. Refer to SmPC for complete list. Reference Number: NHSE(LR)/PGD/Hep A v1.1 Page 5 of 6

Healthcare Professional s Agreement to Practise and Practice/Pharmacy/Local Organisation Authorisation PGDs DO NOT REMOVE INHERENT PROFESSIONAL OBLIGATIONS OR ACCOUNTABILITY. IT IS THE RESPONSIBILITY OF EACH PROFESSIONAL TO PRACTISE ONLY WITHIN THE BOUNDS OF THEIR OWN COMPETENCE AND IN ACCORDANCE WITH THEIR OWN CODE OF PROFESSIONAL CONDUCT. DECLARATION by healthcare professional: I have read and understand this PGD; I have been appropriately trained to understand the criteria listed, and the techniques and record-keeping required to administer the vaccine in accordance with this PGD; The training has included both the theoretical and practical aspects of the techniques required to administer vaccines by the following routes (please tick as appropriate): Intramuscular injection Subcutaneous injection I confirm that I have been assessed for my knowledge and clinical competency, and EITHER am experienced in administering vaccines in the past 12 months, OR I have been observed administering vaccines in practice; I confirm that I am competent to undertake administration of this vaccine; I confirm that I will ensure that I remain up to date in all aspects of the administration of this vaccine. Healthcare Professional s Name:. Registration Number:. Expiry Date:. Signature:.... Date:. Declaration by Authorising Manager * : Managers should only authorise staff who have received the required training and are competent to work to this PGD. Each authorised member of staff should be provided with an individual copy of the PGD, which they should also sign to declare themselves competent. A copy of the signed document should be kept by the individual staff member. The authorising manager should retain a copy of the signed individual authorisation page. I have read and understood the PGD and authorise the staff member named above to operate in accordance with this PGD. Authorising Manager s Name:.. Signature:.... Date:. * The term manager refers to the person taking responsibility for authorising healthcare professionals to operate under the terms of this PGD, and includes lead GPs, nurse managers, pharmacy managers etc. Reference Number: NHSE(LR)/PGD/Hep A v1.1 Page 6 of 6